2025 CSGCT Summit Kicks Off with Global Vision: Four Strategic Advantages Powering Asia-Pacific's Premier Cell and Gene Therapy Event

Aug 07, 2025 14:39 CST Updated 14:39

As small-molecule drugs and antibody therapeutics have successively spearheaded waves of transformation in the pharmaceutical industry, the global life sciences community is now focusing on a “new blue ocean” brimming with infinite possibilities—cell and gene therapy (CGT). This frontier has been regarded by major developed nations and economies worldwide as a strategic high ground for reshaping the future healthcare landscape, prompting them to compete in making substantial investments and accelerating their strategic deployments. With its revolutionary therapeutic potential, CGT technology is breaking through the limitations of traditional pharmaceuticals, bringing hope for a paradigm shift from “symptom management” to “one-time treatment with potential cure” for intractable diseases that have long plagued humanity, including cancer, genetic disorders, rare diseases, and even age-related conditions.

In the face of this global wave of technological and industrial competition, China has demonstrated strong strategic resolve and forward-looking vision. The national 14th Five-Year Plan explicitly prioritizes the research, development, and industrialization of disruptive biotechnologies, such as gene therapy and cell therapy, providing key support through top-level design. Driven by robust national strategies, basic research in China’s CGT sector has achieved continuous breakthroughs, the number of clinical trials has surged exponentially, the industrial innovation chain is rapidly maturing, and a cohort of locally rooted enterprises with global competitiveness has emerged.China is rapidly transitioning from a “follower” to a “peer,” and even a “leader,” in the global cell and gene therapy (CGT) arena. A vibrant and high-potential CGT industrial ecosystem is accelerating its formation in China, contributing increasingly significant “Chinese solutions” and “Chinese wisdom” to the global health cause.

Amid the grand vision of propelling the rise of China’s cell and gene therapy (CGT) industry, Beijing has rightfully emerged as the cradle of CGT innovation and a highland for industrial development in China, leveraging its profound foundations in life sciences, top-tier clinical and research resources, vibrant innovative capital, and a robust industrial ecosystem. With foresight and unwavering determination, the Beijing Municipal Government has prioritized CGT as a key frontier in life sciences and biotechnology. By implementing a series of policy innovations, guiding patient capital, developing specialized industrial parks, and attracting top-tier talent, Beijing has established a comprehensive support system covering the entire value chain—from basic research and technology transfer to clinical trials, pilot-scale manufacturing, and commercialization. Beijing is striving to build a globally influential CGT innovation hub, providing the most fertile ground for the growth of domestic innovators while opening up the smoothest channels for advanced international technologies and capital to enter the Chinese market.

2025 CSGCT Conference

At this critical juncture, where the spirit of the times resonates in sync with national and local strategies,2025 2nd China Cell and Gene Therapy (CSGCT) Conferenceemerged as the times required,scheduled to be held inSeptember 12–13, 2025InZhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading CenterGrand Opening。This conference will be themed “Rooted in Regulation, Harnessing Wisdom, Connecting Globally, Co-Creating the FutureGuided by this core philosophy, the conference closely aligns with the latest developments and scientific guidance in government regulatory policies. It deeply integrates top-tier global regulatory expertise, cutting-edge clinical research resources, substantial industrial capital, and dynamic corporate capabilities. Dedicated to building an authoritative, open, and efficient global dialogue platform, the conference enables key industry stakeholders—including policymakers, scientists, clinicians, entrepreneurs, and investors—to engage in in-depth exchanges of ideas, spark intellectual innovation, and explore collaborative opportunities. With a global perspective, we will thoroughly examine the opportunities and challenges in shaping the CGT industry ecosystem, focusing on core issues such as advances in regulatory science, breakthroughs in technological innovation, pathways for clinical translation, bottlenecks in industrialization, and strategies for global cooperation.

Conference Registration Is Now Open!

Scan the QR code to register now

Four Major Resource Advantages Working in Concert

Striking the Strongest Note in International Cooperation

2025 CSGCT Conference

Strong Support from Government Regulatory Resources

This conference focuses on the latest developments and scientific guidance in government regulatory policies, conducting in-depth discussions centered on core topics such as advances in regulatory science. Numerous government and regulatory officials have gathered together, includingNational Health Commission, National Medical Products Administration, Beijing Municipal Science & Technology Commission, Haidian District People's Government of Beijingsenior officials, who will deliver authoritative insights on policy interpretation and regulatory review and approval to support industrial development, analyzingPolicy Orientation and Regulatory Guidelines, providing direction for industry development, and offering in-depth discussions on the application and interpretation of policies regarding advanced therapy medicinal products (ATMPs) and new clinical technologies, as well as the latest requirements for quality control and testing of cell and gene therapy (CGT) products across various countries, thereby delivering comprehensive and practical regulatory knowledge to practitioners.

Gathering of Top International Experts and Resources

The conference upholds an international perspective, committed to building a global platform for exchange in cell and gene therapy, facilitating the industry's integration into the global innovation network. The conference has invited numerous top international experts and industry leaders to participate, bringing together professionals fromResearch institutions, corporate representatives, and experts and scholars from the United States, Japan, Singapore, Malaysia, and other regions around the world, jointly exploreFrontier Technologies, Clinical Applications, and Industrialization in the Field of Cell and Gene Therapyand other topics, fostering experience exchange and collaboration among different countries and regions. The conference also featured closed-door sessions and other networking activities, providing global participants with opportunities for in-depth communication and cooperation. These efforts aim to align China’s cell and gene therapy industry with international advanced standards, enhance China’s influence and competitiveness in the global cell and gene therapy landscape, and accelerate the transition from a “peer” to a “leader.”

Dr. Wu Zhenhua, the founder of CSGCT and an early participant in ASGCT, has laid a solid foundation for international cooperation for the conference. In addition, the 2025 CSGCT Conference has invited many key international guests in the field of cell and gene therapy (continuously updated), such as:

Professor Mark Kay,Professor of Human Gene Therapy and Genetics at Stanford University; Director of the Division of Human Gene Therapy at Stanford University; Co-founder of the American Society of Gene & Cell Therapy (ASGCT); Former President of ASGCT; Co-organizer of the American Society for Microbiology’s Conference on Viral Vectors; Member of the Executive Committee of the Stanford University Academic Senate. As a founding member and former president of ASGCT, he is recognized as a world-leading expert in gene therapy.

Dr. Jude Samulski,A pioneer in adeno-associated virus (AAV) research, he has dedicated over 40 years to the AAV field and was the first scientist to clone the AAV genome, a discovery that enabled researchers to begin engineering AAV into gene delivery vectors. He co-founded Asklepios BioPharmaceutical (AskBio), a company committed to developing novel AAV vectors as tools for delivering gene therapies. AskBio’s technology has been adopted by multiple companies, including Bayer, Pfizer, Takeda, and Novartis. Last October, Bayer acquired AskBio for approximately $4 billion.

Ms. Sheila Mikhail，She has served as a Director of Verve Therapeutics since April 2021. The company specializes in in vivo gene editing therapies and is dedicated to developing innovative treatments for the prevention of cardiovascular diseases using base editing technology. In 2001, she co-founded AskBio, an AAV gene therapy company, and served as its CEO from April 2017 until its acquisition by Bayer in 2020. She served as CEO of Bamboo Therapeutics, a gene therapy company, from December 2014 until its acquisition by Pfizer in November 2016. From 2010 to 2014, she was a member of the management team at Chatham Therapeutics, which was acquired by Baxter. With over 15 years of legal experience, she founded Life Sciences Law PLLC and served numerous prominent clients. She holds a Bachelor of Science degree from the University of Illinois at Urbana-Champaign, a Juris Doctor from Northwestern University, and an MBA from the University of Chicago Booth School of Business.。

In addition, key opinion leaders such as Haifeng Chen (Vice President and Chief Scientific Officer at Virovek), Zhongyu Zhu (Chief Scientific Officer at Caring Cross), and Loh Hui Pin (Managing Director at AbGenTil) have also confirmed their attendance at the conference.

Gathering Frontier Translational Research Resources

The conference fully demonstrated the abundant resources of cutting-edge translational research in the field of cell and gene therapy. On one hand, top-tier domestic scientific research forces have gathered here, especiallyExperts and scholars from numerous universities and research institutes in Beijing, as well as Grade IIIA hospitals, clinicians, etc., share inBasic Research, Clinical Trials, and Translational Applications in Cell and Gene Therapylatest achievements and practical experience in areas such as gene therapy, stem cell therapy, immune cell therapy, and nucleic acid drugs. On the other hand, the conference also attracted numerous corporate guests, representing the key innovators in the cell and gene therapy industry, who possess extensive experience and resources in translating scientific research into applications. Through close interaction and collaboration between research institutions and enterprises, the conference established an efficient platform for exchanging frontier translational research resources, acceleratingTranslating Scientific Achievements from the Laboratory to Clinical Applications and the Market, driving the rapid development of the cell and gene therapy industry, and providing more effective treatment options for major diseases such as cancer and genetic disorders.

Investment &BD TransactionPrecise ResourcesDocking

The 2025 CSGCT Annual Conference will collaborate with VCBeat (China’s leading innovation service platform for the healthcare industry, covering over 80% of active investment institutions in the pharmaceutical sector) to create a high-quality platform for investment and financing matchmaking. The conference will attract more than 500 investment institutions and corporate investors from around the world, includingEli Lilly Asia Venture Fund, Legend Capital, Qiming Venture Partners,Songhe Capitaland other top-tier institutions,Bayer, Novo Nordisk, Pfizer, Eli LillyWaitMNCThe event will feature exclusive investment roadshows, one-on-one negotiations, and a matchmaking session for overseas financing of Chinese biopharmaceutical companies, providing biotech firms with direct access to domestic and international capital. Robust capital support will empower CGT companies to overcome financing challenges, achieve technological breakthroughs, and accelerate market access.

The conference holds distinct advantages in financing and business development (BD) projects, providing ample opportunities for connecting enterprises with capital. Held during the conference, ChinaBiotechOverseas Financing Matchmaking Conference and Project Roadshow (Clinical Translation) attracted numerous renowned domestic and international investment institutions, providing Biotech companies with a platform for direct communication with investors. The conference also offered 1-on-1 interaction scenarios for participating enterprises, facilitating more in-depth cooperation negotiations between companies and investors, thereby increasing the success rate of financing. In addition, the conference brought togetherLatest Technologies and Products in the Global Cell and Gene Therapy Field, for enterprisesBusiness Cooperation, Technology Transfer, Market Expansion...have provided abundant resources and opportunities, promoted the construction and development of the industrial ecosystem, accelerated the process of cell and gene therapy projects from research and development to industrialization, and injected strong momentum into corporate growth and industry development.

The conference fully highlighted the abundant resources in cutting-edge translational research within the field of cell and gene therapy. On one hand, top-tier domestic scientific research forces have converged here, especiallyExperts and scholars from numerous universities, research institutes, and Grade 3A hospitals in Beijingclinicians, etc., share inBasic Research, Clinical Trials, and Translational Applications in Cell and Gene Therapythe latest achievements and practical experience in areas such as gene therapy, stem cell therapy, immune cell therapy, and nucleic acid drugs. On the other hand, the conference also attracted numerous corporate guests, representing the key innovators in the cell and gene therapy industry, who possess extensive experience and resources in translating scientific research into practical applications. Through close interaction and collaboration between research institutions and enterprises, the conference established an efficient platform for exchanging frontier translational research resources, acceleratingTranslating Scientific Achievements from the Laboratory to Clinical Applications and the Market, accelerating the rapid development of the cell and gene therapy industry, and providing more effective therapeutic approaches for addressing major diseases such as cancer and genetic disorders.

Comprehensive Coverage of Cutting-Edge Topics

Addressing Industry Pain Points and Bottlenecks

2025 CSGCT Conference

The conference closely addressed the industry’s hotspots, pain points, and bottlenecks, featuring 1 main forum + 8 high-end sub-forums, coveringGlobalization of China’s Cell and Gene Therapy Industry; Latest Advances and Applications in Global Gene Therapy, Immune Cell Therapy, Stem Cell Therapy, and Nucleic Acid Drugs; Recent Progress and Applications in CMC and Testing; Latest Clinical Exploration Advances in the Global CGT Field; AI-Driven Drug R&D; Overseas Financing Matchmaking; Interpretation of the Latest Policiesand other key issues, achieving in-depth coverage of the entire cell and gene therapy industry chain.

In the field of gene therapy, an in-depth discussion will be conductedGene Editing, Vector Optimization, and Rare Disease Therapybreakthrough achievements in the field, pointing the way for the future development of gene therapy, and will also explore gene therapy inOphthalmology、OtologyandCNSandRare Diseasestherapeutic prospects in disease areas such as... The cell therapy segment focuses onAllogeneicCAR-T，invivo CAR-T，iPSCTechnologythe application prospects of cutting-edge therapies in disease areas such as solid tumors, non-solid tumors, immune diseases, and neurodegenerative diseases, sharing the latestInnovative Design、Clinical Research Data andAdvances in Cancer Treatment. As an emerging hotspot in recent years, nucleic acid therapeutics will be featured at the conferenceFocusTherapeutic Cancer VaccinesofDevelopment and Combination Therapy，andNovel Delivery Vectors for Nucleic Acid TherapeuticsDevelopment and Indication Expansion, analyze the key scientific issues in the R&D process of nucleic acid drugs and the challenges faced in industrialization, to facilitate the translation of this field from laboratory to clinical practice and market.

Due to their inherent characteristics and complexity, the manufacturing processes of cell and gene therapy (CGT) products are more complex than those of small-molecule chemical drugs or other biologics. Challenges such as testing of final CGT products, product release testing, and specification setting have long been persistent difficulties in the early-stage development process for companies. In light of this, the conference has specially organized a forum on the latest advances and applications in CMC and testing within the global CGT field, which will focus onFrontier Innovations and Development Trends in Manufacturing Processes and Quality Characterization of CGT Products、How to Build a CompliantCommercialized Production System for CGT Products with Market-Oriented Characteristics (Process Validation, MAH Category B License, Production Line Design, etc.)Frontier Innovations and Development Trends in CGT Product Manufacturing Processes and Quality CharacterizationWaitIn-depth analysis to help enterprises tackle critical CMC challenges in the product development lifecycle and overcome quality compliance barriers in CGT product development.

Looking at the landscape in China and globally, an increasing number of companies are beginning to lay out their CGT (Cell and Gene Therapy) pipelines. How to substantially address the issue of commercial accessibility of products has become the most clear-cut challenge facing the industry today. In light of this, the 2025 CSGCT Conference will bring “How to PromoteAchieving a Sustainable Commercialization Pathway in the CGT Sector" cross-domain dialogue,AnalysisProductBreakthrough Points for Commercial Value，ExploreProductImplementationBusinessTransformationYesEfficacyandHigh EfficiencyofPathways and Patterns。

Meanwhile, the conference also focuses on the enabling role of AI technology in cell and gene therapy, analyzing how AITarget Discovery, Drug Design、Vector Constructionand production automationapplication potential in these areas, offering new perspectives for the industry’s digital transformation. For enterprises, overseas financing serves as a crucial support for achieving technological breakthroughs and market expansion. To this end, the conference has specially organized the China Biotech Overseas Financing Matchmaking Conference and CGT Project Roadshows to analyzeCore Logic of CGT Product Pipeline Layout and Value Investment, to establish a precise matchmaking platform for domestic enterprises and overseas investment institutions, helping companies broaden their financing channels and accelerate their international expansion.

The closed-door policy interpretation session brings together experts from regulatory agencies,In-Depth Analysis of the Latest Product Registration Trends and Regulatory Dynamics in Cell and Gene Therapy in China and AbroadPolicy and Regulatory Requirements, helping enterprises achieve compliant development and mitigate risks, while driving innovation and sustainable growth in the industry under policy support.

Whole-Chain Resonance, Venture Capital Co-Field

2025 CSGCT Conference

The 2025 CSGCT Conference will bring together participants from around the world300+ Top Industry Experts from China and Abroad、500+ Investors/Investment Institutions，and 3,000+ elite professionals and specialized attendees in the field of cell and gene therapyparticipation. Among them,Cell and Gene Therapy Companies & CGT Research Institutions and ScientistsAccounting for over 52%,CGT-related USD and RMB fund investors, strategic industry investors, and financial services institutionswhen the proportion exceeds 10%, to build an efficient investment and financing matchmaking platform for companies in the CGT sector; furthermore,Clinical institutions and physicians, patient organizations, regulatory agenciesas the audience will also be present to participate, helping to drive the resolution of challenges facing China’s CGT industryDifficulties in Commercialization, Fundraising, and Regulatory Approval; High Risks...and other industry pain points and bottlenecks, to promote the deep integration of the entire industrial chain encompassing production, academia, research, application, regulation, and investment.

Distribution Map of Core Attendees

In-Depth Exploration Tour of China's CGT Industry

Clinical Practice, Policy Interpretation, and Global Collaboration

2025 CSGCT Conference

If you wish to gain a deeper understanding of the ecosystem of China’s cell and gene therapy (CGT) industry and the authentic state of its development, to foster collaborations with Chinese clinicians, patient advocacy groups, enterprises, and regulatory authorities, and to engage in in-depth exchanges with global pharmaceutical executives, clinical research leaders, and investment partners, we have meticulously curated a one-week intensive immersion program into China’s CGT industry (September 10–16). This program will offer:

✦

•

✦

2025Year9Month12-13Day

2025 2nd China Society for Gene and Cell Therapy (CSGCT) Conference

Golden Autumn in September, Gather in Haidian, Beijing!

For more details, scan the QR code to visit the official conference website.

Inquiries for Speaking/Sponsorship/Exhibition & Business Cooperation

Ms. Li 18600921680 (WeChat ID same)

Registration / Business Delegation Inquiry

Ms. Ren 15111945514 (WeChat ID same)

Previous Attendees

2024 CSGCT Conference

Past Editions Review

2024 CSGCT Conference